Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Scholar Rock Holding Corporation - Common Stock (NQ:SRRK)

45.99 +2.01 (+4.57%)
Delayed Quote Updated: 1:54 PM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Scholar Rock Holding Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Scholar Rock to Present at Upcoming Investor Conferences
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
From Scholar Rock
Via Business Wire
Scholar Rock (NASDAQ:SRRK) Rallies 17% as Regulatory Catalysts Outweigh In-Line Q2 Results ↗
Via Chartmill
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Present at Upcoming Investor Conferences
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab ↗
Scholar Rock (NASDAQ:SRRK) CEO David Hallal said the company is preparing for a September 30 FDA decision date for apitegromab, its investigational treatment for spinal muscular atrophy, or SMA,... 
Via MarketBeat
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock, Inc.
Via Business Wire
News headline image
Scholar Rock (SRRK) Q2 2026 Earnings Call Transcript ↗
Apitegromab awaits FDA decision on Sept. 30 for spinal muscular atrophy treatment. 
Via The Motley Fool
Topics Earnings Economy
News headline image
Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Q2 Earnings Call Highlights ↗
Scholar Rock (NASDAQ:SRRK) said its resubmitted biologics license application for apitegromab remains on track for a U.S. Food and Drug Administration decision by its Sept. 30 PDUFA date, as the... 
Via MarketBeat
Topics Earnings
News headline image
Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference
From Scholar Rock, Inc.
Via Business Wire
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock, Inc.
Via Business Wire
News headline image
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗
Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO ↗
Veradermics develops novel dermatology treatments, targeting both adult and pediatric markets with a research-driven approach. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% ↗
This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway-driven cancers, addressing hard-to-treat tumor types. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Scholar Rock Q1 Earnings Call Highlights ↗
Scholar Rock (NASDAQ:SRRK) said the U.S. Food and Drug Administration has accepted for review its resubmitted Biologics License Application for apitegromab, the company’s investigational treatment for... 
Via MarketBeat
Topics Earnings
News headline image
Scholar Rock (SRRK) Q1 2026 Earnings Transcript ↗
Scholar Rock (SRRK) Q1 2026 Earnings Transcript 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.